John Carl Panetta

9PUBLICATIONS
39CO-AUTHORS
Infant and child healthPharmacogenomicsHaematologyHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Apr 21, 2026
Impact of Dosing Interval Adherence on Pharmacokinetic Outcomes of Recombinant Erwinia Asparaginase in Pediatric Leukemia or Lymphoma.

|Oct 28, 2023
The Combination of Predictive Factors of Pharmacokinetic Origin Associates with Enhanced Disease Control during Treatment of Pediatric Crohn's Disease with Infliximab.

Marla C Dubinsky, Shervin Rabizadeh, John C Panetta

|Oct 17, 2023
Treosulfan Exposure Predicts Thalassemia-Free Survival in Patients with Beta Thalassemia Major Undergoing Allogeneic Hematopoietic Cell Transplantation.

Aswin Anand Pai, Ezhilpavai Mohanan, John C Panetta

|Aug 24, 2022
Preclinical evaluation of proteolytic targeting of LCK as a therapeutic approach in T cell acute lymphoblastic leukemia.

Jianzhong Hu, Jamie Jarusiewicz, Guoqing Du

|Jun 24, 2022
Model Informed Precision Dosing Tool Forecasts Trough Infliximab and Associates with Disease Status and Tumor Necrosis Factor-Alpha Levels of Inflammatory Bowel Diseases.

Christian Primas, Walter Reinisch, John C Panetta

|Mar 28, 2022
Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication.

Hiroto Inaba, Jolieke G van Oosterwijk, John C Panetta

Pageof 2

Frequent Collaborators

5 joint publications

Ching-Hon Pui

4 joint publications

Hiroto Inaba

3 joint publications

Seth E Karol

2 joint publications

Hope D Swanson